论文部分内容阅读
Objective: To investigate thecorrelation between the EGFR expression profile, FGFR gene mutation and clinicopathological characteristics,in order to provide evidence for the treatment of ovarian carcinoma with EGFR-TKIs.Methods:Ninetie-six patients with FIGO stageⅢ and Ⅳ epithelial ovarian Cancer who were treated in the Sun Yat-sen University Cancer Center From Jan2003 to April 2009 were included.The EGFR expression was examinated in paraffin-embedded cancer tissues withan immunohtstochemisty assay.Real-time PCR was employed to detect EGFR gene mutations.Chi-square test was used to analyze the correlation between the EGFR expression level and clinicopatjological characteristics.The clinicopathological characteristics of patients with EGFR gene mutation wene recorded.Kaplan-Meier method and cox regression method were utilized for survival analysis.Results: EGFR expression rate was 78.2% in all cases with different leveis.Patierts who had stage Ⅲ disease, with poorly differentiated tumor, with ascites cytology positive, and who underwent suboptimal cytoreluction presented expression levels of EGFR in their tumor tissue.Four specimens harbored tyrosine kinase donain mutations and had in-drame deletion of 15 nucleotides (2235de115;E746_A750del) in exon 19 of the EGFR gene.These four patients presented with similar clinicopathological characteristics.they wae,older than 50 years st diagnosis,had FIGO stageⅢC disesse,and had poorly differentissed disease with high expression levels of RGFR.Survival analysis showed that only pathological type was an independent prognostic factory.Patients with serous adenicarcinome indicated longer overall survival for patients(p=0.019,HR1.464,95%CI 1.065~2.011).Patients with low expression of EGFR had 16.8 months longer overall survival than those with high expression level (p=0.143).Conclusion:EGFR expresses in most of the advanced epithelial ovarian cancer tissues.The older Patients with high levels of EGFR expression with advanced disease and poorly differentiated ovarian carcinomas are likely to harbor the EGFR mutation R746_A750del.